Luxa Biotechnology Awarded $4 Million CIRM Grant to Support Clinical Trial of Adult RPESC-RPE-4W Therapy for Dry Age-related Macular Degeneration

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul, South Korea and the Neural Stem Cell Institute (NSCI) in Rensselaer, New York, today announced receipt of a $4 million grant from the California Institute for Regeneration Medicine (CIRM) to support the ongoing Phase 1/2a study (NCT04627428) of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). The funding will accelerate manufacturing